NCT01153100View on ClinicalTrials.gov

Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Diabetes
Interventions
DRUG

Glargine

Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy

Trial Locations (1)

80045

University of Colorado Denver, Aurora

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of Colorado, Denver

OTHER